Bizantine Capital (@Bizantinecap) header
Bizantine Capital (@Bizantinecap) profile picture

Not investment advice - https://xitter.cf/t.co/M03QDsSzup

Joined October 2021
Photo by Bizantine Capital (@Bizantinecap)Photo by Bizantine Capital (@Bizantinecap)Photo by Bizantine Capital (@Bizantinecap)Photo by Bizantine Capital (@Bizantinecap)Photo by Bizantine Capital (@Bizantinecap)Photo by Bizantine Capital (@Bizantinecap)Photo by Bizantine Capital (@Bizantinecap)Photo by Bizantine Capital (@Bizantinecap)Photo by Bizantine Capital (@Bizantinecap)Photo by Bizantine Capital (@Bizantinecap)
We all know Hair-loss treatment is overdue for a breakthrough. If topical diazoxide can deliver meaningful, lasting regrowth with a strong safety profile, this could be more than another product launch... it could open a whole new chapter. We are looking forward to the clinical results.
Minoxidil and finasteride were discovered by accident. Topical diazoxide was built on purpose. It goes live tomorrow.
5
378
Bizantine Capital retweeted
Everyone’s arguing about AI replacing jobs. I’m watching whether it can improve medicines people actually use. If MINX delivers comparable efficacy with fewer side effects in rigorous trials, “product of the year” won’t be hype. It’ll be earned :).
still 2026 product of the year
2
4
107
Love seeing AI applied to practical problems like drug delivery. MINX’s focus on smoothing blood-level peaks is an exciting and asymmetric direction. Rooting hard for the team and looking forward to larger controlled studies on safety and efficacy. 👏
Replying to @anagenxyz
Which MINX dose is right for you? MINX comes in 1.25, 2.5, 5 and 7.5 mg forms. It depends on your weight, heart health and regrowth goals. Keep us posted on your journey. Our community of MINX patients is active on X and Discord. (10/10)
3
126
Really encouraging early results. The goal makes sense: get the treatment to hair follicles while limiting how much reaches the rest of the body. Still early, but this looks like a promising direction for people worried about side effects.
Most topical hair loss products lower DHT everywhere in the body. Potential side effects include: > decreased reproductive health > brain fog > breast tenderness or enlargement We designed Precision Dutasteride to stay local in the hair follicle. @VerbinnenAndrew applied 1 mL of 1% Precision Dutasteride a day on a damp scalp. @zach_schrier doubled to 2 mL a day on a dry one. Both for 4 weeks. Andrew had 0.157 ng/mL of dutasteride in his blood, and Zach 0.282 ng/mL. Oral dutasteride (0.5mg) puts you at 36.1 ng/mL. 128-230x more. Based on our serum dutasteride readings, we modeled a 7% drop in blood DHT from 1% Precision Dutasteride, 1 mL per day. By comparison, oral dutasteride lowers DHT by 95%. Even though Precision Dutasteride 1% is 20x more Dutasteride (10 mg’s applied topically). AND from our pre-clinical study with Prof. Tais Gratieri, 64% of topically applied Precision Dutasteride goes straight to the follicle - 2-3x more than other popular dutasteride vehicles. We modeled what we believe this means for 0.03% Precision Dutasteride Lite and 0.3% Precision Dutasteride. Read the full report -> anagen.xyz/treatment-science…
5
179
Another example of how powerful MINX is. @anagen's top product is designed to keep minoxidil working in your system for longer which supports hair growth throughout the day. At the same time, it's staying well below the blood levels linked to side effects.
In Upjohn’s minoxidil clinical trial, cardiac side effects began at 21.7 ng/mL of minoxidil in blood. In Bokhari’s sublingual minoxidil study, hair growth began with a peak minoxidil exposure of about 1.6 ng/mL. We designed MINX to stay between these two bands for as much of the day as possible. In the fed state, MINX stayed above 1.6 ng/mL for a modeled 8+ hours. MINX’s modeled peak was 6.5 ng/mL, ⅓ of Upjohn’s 21.7 ng/mL read out. Our community is an open book. You can chat with them about their MINX experience on X or Discord.
1
4
339
Patients deserve access, choice, and transparency. We we stand with MINX.
⚠️ Alarming: Veradermics ($MANE) has sent a Cease & Desist to another one of our pharmacy partners. They’ve now contacted several of our pharmacies and our doctor network. Why doesn’t a big pharma want you to have access to MINX? Their lead drug candidate, VDPHL01, is an extended release minoxidil tablet. The company, Veradermics Incorporated, seems to view MINX as a competing product. Find the full video on our YouTube channel to learn more about what makes MINX different. MINX will continue shipping.
1
10
284
Perps brought leverage onchain. Options bring an actual volatility market. The hard part isn’t launching an options UI... it’s solving liquidity, margin, execution, and risk at scale. That’s the $DRV opportunity.
After listening to Jeff's DAS interview, my $DRV bull thesis is unchanged, and possibly strengthened. No, this isn't cope. Strap in for a long one. First off, it was framed in a terribly misleading way by CoinTelegraph for clickbait (shocking). Jeff was asked if we he wasn't forced to be focused on perps infra, their core business, and was instead a 3rd party builder, what would he find interesting to build. His answer was that he'd look for whatever hadn't really been built yet, and mentioned options as a good example. He then added that they're tremendously important as an instrument in TradFi, so figuring out why that hasn't translated over to crypto would be an interesting problem to solve. He then added that HIP4 is already their attempt at building the infrastructure to allow teams to build options on @HyperliquidX. There are dozens of teams building binary options already using HIP4 infrastructure. There are several teams building vanilla options on top of Hyperliquid already. None of these products have taken a meaningful bite out of @DeriveXYZ market dominance yet, and they are live right now. He didn't say that they were building options in house, he just said that someone should build options on chain because there's a massive gap between the success and traction they've had on chain vs in TradFi. This is extremely validating of the $DRV thesis. People need to realize and remember that @DeriveXYZ wasn't specifically written off for all these years, the entire sector of on chain options was deemed as impossible and uninvestable. We've heard, "Options can't exist on chain, options are obsoleted by perps, no retail crypto traders will learn to trade options, etc etc". Jeff negated all of the FUD that on chain options have received over the years and basically said it was the place to be right now. Jeff did specifically say that no on chain options protocol has reached "escape velocity" yet. So if you read between the lines, he's basically saying that on chain options are interesting and necessary as a tool, that they're nascent in their growth as compared to TradFi TAM, and that it's one of the most interesting spots of the market to be focused on building right now. $DRV pumping 10x and having insane hockey stick volume growth YTD isn't "escape velocity" in his eyes, and he's right. $DRV is still cheap and early relative to the market it's expanding into. Job's not finished by any means. It's important to highlight that unlike Vlad from @Lighter_xyz who explicitly says they are building options in house, Jeff said nothing of the sort. Hyperliquid sees themselves as building the neutral infrastructure layers of liquidity for builders to come and build on top of. Look at TradeXYZ and HIP3. He didn't say that they hired a team of 20 ex-Optiver and ex-SIG guys to be their internal options trading desk, he didn't insinuate a launch date, he didn't say HIP-5 is vanilla options. He basically said, "On-chain options are cool and underexplored, I hope teams come and build them on top of our existing infra". Sidenote, I actually think his description of priority fees was actually way more signal and very bullish $HYPE. Way more bullish priority fee growth and obviously AQAv2 fees than anything HIP4 related. At the end of the day, none of what he said is new information. I always have stated in my $DRV bullposts that they will not maintain their current 90%+ market share in 2027. This is an entire primitive that does quadrillions of dollars in volume in TradFi. The on chain pie will grow massively. There will inevitably be more competition for that pie. $DRV could lose half their market share to @Lighter_xyz and @HyperliquidX and still be cheap here at these prices when on chain options volume 10x's or more. I'd also like to point out the irony that I'm long $HYPE and $LIT calls on @DeriveXYZ right now, and I still can't long $DRV perps on Lighter or Hyperliquid. I just refuse to subscribe to this notion that I should sell a phenomenal asset today because maybe there will be competition tomorrow, or next month, or next year. When they have live products, I'll reaccess the situation. Until then, competing against non-existent products that are just presumed to be superior is an unfair standard that seemingly only $DRV gets held to, and irrational selloffs like today, especially based off misleading headlines, are just better entries for me in the long run.
2
1
4
79
MINX’s edge is DELIVERY. @anagenxyz has redesigned how oral minoxidil enters the bloodstream to aim for more controlled, consistent exposure.
This is the story of MINX. Oral minoxidil is the most effective hair pill in the world today. We redesigned how it enters your blood. (1/10)
3
9
1,100
These are our Guys! GLP-1s are clearly changing the longevity conversation. @anagenxyz offers MINX, arguably the cheapest GLP-1s on the market. For eligible patients, in Prescription Only.
Drugs that have shown anti-aging effects in humans: > Semaglutide > Minoxidil > Tretinoin > Retinol > Rapamycin > Everolimus > Dasatinib + quercetin > Estrogen (HRT) > Growth hormone + DHEA + metformin Most of these trials are small and not replicated. More data is needed.
3
129
The investable question isn’t whether doxycycline is “good” or “bad.” It’s whether DOX can turn a known, cheap generic into a defensible, clinically validated product. @anagen We Believe In!
Daily doxycycline for STIs is incredibly dumb. Someone should tell Clavicular. Every time you take an antibiotic, the bacteria that survive it are the resistant ones. He's breeding resistant bacteria inside his body. That's why doxy-PEP is a SINGLE 200 mg dose within 72 hours after sex. Doxycycline has a second job that has nothing to do with killing bacteria. At low doses, it calms inflammation and blocks the enzymes that break down collagen. At those sub-antimicrobial doses, years of studies found no change in antibiotic resistance in the mouth or gut. That's DOX. Low dose doxycycline, built for skin aging, hair growth, and longevity. Patented and coming soon.
3
251
How does smooth release MINX reduce water retention compared with regular oral minoxidil?
Oral minoxidil can give you eye bags 🧵 Bob had them for years on 2.5 mg oral minoxidil. Two weeks after switching to 5 mg of our smooth-release MINX: "Completely lost any/all water retention and darker eye bags I had."
1
70
Something that actually works without wrecking people is rare. @anagenxyz is building while incumbents stall.
Most bullish part of this is the top right corner being empty. Nothing that actually works is wrecking people anymore. Topical fin getting strong results with *basically* no sides is wild (ofc not medical advice, dyor)! @anagenxyz is innovating while the incumbents drag their feet.
2
43
Nice Observatory! trim the dose, keep most of the upside, and cut the chance of a painful drawdown.
🚨 NEW PAPER ALERT 🚨 Finasteride wrecking your libido? You might not have to quit. A new study in JAAD from Rodney Sinclair's clinic in Melbourne looked at 5,675 men on oral finasteride. 100 of them developed sexual side effects. What happened next depended on what they did. > Stopped finasteride: side effects resolved in 96% > Lowered their dose: resolved in 75%, and they kept treating their hair > Stayed on the same dose: only 50% resolved Five men couldn't tolerate even the lowest oral dose, so they switched to topical finasteride. None of them reported sexual side effects. Why does a lower dose still work? Finasteride hits a ceiling. At just 0.2 mg it cuts scalp DHT by 56.5%. The full 1 mg only gets you to 64.1%. For some men, that last bit of DHT suppression costs a lot more in side effects than it buys in hair. Two caveats. It's a small, retrospective study. And tapering took patience, about 7 months on average for side effects to clear. If side effects are why you quit finasteride, this is worth bringing to your doctor.
24
Bizantine Capital retweeted
On September 1st, we filed a PGR against Veradermics Inc. to invalidate their patent US 12,491,184. We did this after they sent cease & desists to us and our compounding pharmacies to prevent our sale of MINX, smooth-release oral minoxidil. Full video linked below.
4
9
4
46
9,635
Bizantine Capital retweeted
$HAIR is moving to @RobinhoodCrypto on Monday. $LAB is live on @solana. We’re the largest hair lab in the world. What do you think will happen?
Your bacon consumption may help us find the cure to hair loss. The best model to study drug delivery is pig ear ex vivo. We used the pig ear model to test over 60 topical dutasteride candidates, ultimately leading to Precision Dutasteride. We've now perfected the model in-house, and will use it to test all topical formulations going forward. The model tells us how much drug is entering the follicle versus the surrounding skin. First, Precision Dutasteride. Now, our lead Diazoxide candidates. Then, what's next? Pigs are smart, beautiful creatures. They may also be our best chance at developing perfect topical hair growth treatments. Learn more → anagen.xyz/treatment-science…
5
5
4
29
4,956
2K BOOM. $ETH is now setting up for a Q4 run toward $3K. Since the Aug. 19 low near $1,905 , ETH has rallied roughly 32% to ~$2,517, while spot ETH ETFs logged 8 straight positive-flow sessions totaling about $1.18B. The last 5 sessions alone: +$891M . Key structure now: turn $2.3K into confirmed support. Hold that, and $3K becomes the next major magnet.
$ETH to 3k in Q4. ETF flows are accelerating, and we have held the local bottom. Lets flip 2k into support.
1
167
Let the results do the talking!
This quoted post is unavailable.
2
3
162
Here we go!
Cross-Sectional Factors are live in Minara Strategy Studio. Hundreds of premium factors, all callable in plain language. Build, tune, and deploy on top equities. 💎
1
137